Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years

Inclusion Criteria: 1. Aged 12 years and above (inclusive), regardless of gender. 2. Voluntarily sign the informed consent form (legal guardians sign for minors \<18 years old, with minor assent if needed). 3. Confirmed diagnosis of cystic fibrosis (CF) with clinically stable condition. 4. Weight ≥40 kg (≥18 years old) or ≥30 kg (\<18 years old), or deemed eligible by the investigator. 5. Predicted FEV1 ≥40% of the normal value and resting SpO2 ≥92% at screening. 6. SAD trial participants: ≥3 months after last dose, no residual CFTR protein/mRNA in nasal epithelial cells (confirmed by lab tests). 7. Quit smoking for at least 2 years. 8. Willing and able to comply with all study procedures and follow-up plans. Exclusion Criteria: 1. Acute respiratory/pulmonary events, significant hemoptysis, or changed CF respiratory medications within 1 month before the first dose. 2. Infected with highly virulent bacteria (e.g., \*Burkholderia cepacia\*, \*Mycobacterium abscessus\*), except for controllable colonization without clinical symptoms. 3. Clinically significant ECG abnormalities (e.g., prolonged QTcF: male \>450ms, female \>460ms) at screening. 4. Abnormal liver/kidney function at screening (TBIL \>ULN, ALT/AST \>3×ULN, CRE ≥1.5×ULN). 5. History of solid organ/bone marrow transplantation or on transplant waiting list. 6. Positive HIV, syphilis, HBsAg or HCV antibodies at screening. 7. Participated in inhaled drug/device studies or used CFTR modulators within 30 days before screening. 8. Pregnant or lactating females. 9. A history of allergies to inhaled drug components or other allergies deemed contraindicated by the investigator. 10. Any other medical conditions/circumstances that may interfere with the trial (judged by the investigator)